The study is funded by an initial grant from the UCLA School of Nursing and intended to identify a low cost diagnostic solution for cervical cancer screening in resource-poor areas.
QuantRx has said that of PadKit collection system plays an effective role in sample collection for in-vitro diagnostic tests. The system helps access to cervical cancer screening in high-risk populations with low-cost.
Dorothy Wiley, associate professor of the UCLA School of Nursing, said: “We are thrilled to work with QuantRx in testing their Padkit intralabial pad, which we hope will improve access to cervical cancer screening in high-risk populations. Our research focuses on cervical cancer, and unfortunately many women cannot afford to be regularly screened.
“Our goal is to demonstrate that Padkit can be used for Pap test self-collection, especially in resource-poor areas with sparse medical facilities. The Padkit is a low-cost and simple method that we believe can meet this need.”
William Fleming, chief scientific officer and president of diagnostics group at QuantRx, said: “This effort will help validate the scientific research, product development and patient studies previously undertaken and funded solely by QuantRx.
“The synergy of the prestigious UCLA School of Nursing and our experience at obtaining in vitro diagnostics with demonstrable diagnostic value has the prospect of resulting in a product used in the fight against cervical cancer that will both reduce the cost of treatment and affordably bring new healthcare applications to market.”
